Objective. To evaluate prognostic factors that impact on the survival of women with ovarian sex cord stromal tumors (SCST). Methods. Data including age at diagnosis, stage, histology, grade, treatment, and survival were extracted from the 1988-2001 Surveillance, Epidemiology, and End Results Program. Kaplan-Meier and Cox proportional hazards analyses were used to determine the predictors for survival.
Introduction
Sex cord stromal tumors (SCST) are rare tumors comprising less than 5% of all ovarian malignancies. The majority of SCST are granulosa cell tumors, with Sertoli-Leydig cell tumors and theca cell tumors accounting for the remainder of this group. Compared to epithelial ovarian malignancies, SCST tend to present at a younger age with a peak occurrence in the 5th to 6th decade of life.
SCST generally behave in an indolent fashion characterized by early stage at presentation, slow growth, late recurrence, and an overall favorable prognosis. Several clinical and pathological prognostic factors have been reported in the literature, including stage, age, tumor size, and grade. Primary therapy for SCST generally begins with standard surgical staging including a total abdominal hysterectomy and bilateral salpingo-oophorectomy. For younger patients with early-stage disease, conservative surgery has been suggested as a treatment alternative for those wishing to retain fertility. However, there is limited evidence in the literature to support the safety of this approach.
The current literature on sex cord stromal tumors of the ovary consists mainly of single or multi-institutional reports with small number of patients, leading to limited and often inconsistent conclusions. Large population-based tumor databases may offer a unique opportunity to collect information on this rare disease. This study identified a large group of women with sex cord stromal tumors of the ovary, and report on the clinical and pathological prognostic factors that influenced outcome. Furthermore, we analyzed the risk associated with conservative surgery in younger patients with early-stage disease.
Materials and methods
Demographic, clinicopathological, treatment, and survival information of all women diagnosed with SCST of the ovary during the period from January 1st, 1992 to December 31st, 2001 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database of the United States National Cancer Institute. Data are reported from 12 population-based registries that represent approximately 14% of the U.S. population [1] . Information on age at diagnosis, FIGO stage, grade, and tumor size was also extracted. Primary surgical treatment was categorized into three groups: no surgery, standard surgical staging including a hysterectomy, and conservative uterine-sparing surgery.
Statistical analysis was performed using the Intercooled STATA 8.0 program (College Station, TX). Survival analysis was performed using the Kaplan-Meier estimates of survival probability, and the Cox-proportional hazards model was used to identify independent predictors of disease-specific survival. A two-sided p-value <0.05 was considered statistically significant.
Results
A total of 376 women with sex cord stromal tumors of the ovary were identified. 339 of these patients had granulosa cell tumors and 37 (10%) had Sertoli-Leydig cell tumors. The median age of women in this group was 51 years (9-93). 280 (75%) of patients were Caucasian, 65 (17%) were Black, 18 (5%) Asian, and 13 (3%) of other racial backgrounds (Table 1) .
234 women (63%) received standard primary surgical staging that included a hysterectomy, whereas 129 (34%) underwent surgical treatment without hysterectomy. 70% of patient presented with stage I disease, 10% stage II, 11% stage III, and 9% with stage IV cancers. Of the 106 patients with information on grade, 65 (61%) had low grade (1-2) disease and 41 (39%) had grade 3 disease. Tumor size was recorded for 210 cases with a median size of 11 cm (range: 0.5-50).
The overall 5-year and 10-year disease-specific survival for all patients was 88% and 79%. Patients with early-stage (Stage I-II) disease had a 5-year and 10-year survival of 95% and 84%, compared to only 59% and 57% for those with advanced stage disease (p < 0.001) (see Fig. 1 ). Younger women (≤ 50 years) had a 5-year survival advantage over older (> 50 years) women (93% vs. 84%, p < 0.001) (see Fig. 2 ). Patients with grade 1-2 tumors had better 5-year survival than those with grade 3 disease (96% vs. 64%, p < 0.001) (see Fig. 3 ). Tumor size was not an important predictor for survival; for, those with tumors ≤ 10 cm vs. > 10 cm had a survival of 91% vs. 89%, respectively (p = 0.42).
To determine the outcomes of young women who underwent uterine-sparing procedures, we analyzed the survival for the group of 134 younger patients (≤50 years) with stage I disease. The outcome for this group of young patients with stage I disease was excellent with a 5-year and 10-year disease-specific survival of 97% and 94%. Sixty-one (46%) of these patients underwent standard surgical which included a hysterectomy and 71 (54%) had a uterine-sparing procedure. There was no difference in the outcome of women who had a standard vs. conservative surgery (97% vs. 98%, p = 0.61).
The factors that were significant in univariate analysis were then analyzed in a multivariate analysis using the Cox proportional hazards model. Younger age at diagnosis (hazard ratio = 1.03; 95% C.I. = 1.01-1.05) and early-stage (Stage I-II) of disease (hazard ratio = 1.79; 95% C.I. = 1.43-2.25) remained as significant prognostic factors for improved disease-specific survival ( Table 2) .
Discussion
Ovarian sex cord stromal tumors (SCST) are relatively rare malignancies. As such, most studies of this disease have been hindered by small number of patients that limit conclusive statistical analysis. To our knowledge, this current report represents the largest series of women with sex cord stromal tumors in the literature. Consistent with the well-known indolent nature of this disease, our series showed an extremely favorable prognosis with 5-year disease-specific survival approaching 90%. In contrast to epithelial ovarian cancers, patients with SCST generally present at a younger age with almost 50% of the women in our study presenting under the age of 50. Furthermore, these patients tend to have early-stage disease as reflected by the 80% of women with stage I-II disease at diagnosis. The prognostic significance of age in SCST has been controversial. Of the larger two series in the literature, both having over 90 patients, older age was associated with a decreased survival [2, 3] . Specifically, patients older than 40 had a corrected survival of 64% compared to 81% in those younger than 40. In contrast, Bjorkholm and colleagues reported on 198 patients but did not find any significant impact of age on survival [9] . In this current series of 376 women, younger women age ≤50 years had a 10% survival advantage over their older cohorts. The younger patients had a trend towards having earlier stage of disease compared to the older women (83.4% vs.
78.7%, p = 0.25) which may have contributed to the better outcome of the younger group. However, age at diagnosis remained a significant prognostic variable in multivariate analysis after accounting for stage and grade of disease. It is unclear why there are marked differences in prognosis for different age categories. Age-associated clinical determinants such as a better performance status and a tendency for clinicians to treat younger patients more intensively may contribute to this difference but do not completely explain it [4] . An intrinsic difference in tumor biology in women of different ages is a possible factor. Chan and colleagues analyzed the differences in prognostic molecular markers between women over and under 45 years of age with advanced epithelial ovarian cancer and found that tumors of older women had significantly lower microvessel density (MVD) compared to younger women. Lower MVD was a significant independent prognostic factor for decreased survival. Therefore, lower frequency of neovascularization in these cancers may contribute to the survival differences observed in these two age groups [5] . Mitotic index, lymphovascular invasion, cellular atypia, and absence of Call-Exner bodies have been demonstrated to be independent prognostic factors significant in adult granulosa cell tumors [6, 7] . Clearly, molecular analyses on ovarian stromal tumors may further elucidate the differences in outcomes of women in different age groups.
Stage of disease has been shown to be the most important prognostic factor in most studies [2, 3, [8] [9] [10] [11] . Even in studies with long-term follow up, the 10-year survival rate of stage I, II, and III-IV is 84% to 95%, 50% to 65%, and 17% to 33%, respectively [12, 13] . Similarly, in this current series, we found that patients with stage I-II disease had a survival advantage of 36% compared to those with stage III-IV cancers. Tumor size greater than 10 to 15 cm is associated with inferior survivals in some reports. In the study by Miller et al. of 70 patients, larger tumor size (13.5 cm vs. 10 cm) was associated with decreased progression-free survival, but this difference was no longer important in multivariate analysis after accounting for stage of disease. In a multi-institution series of 83 patients, Chan et al. showed that tumor size ≥ 10 cm contributed to decreased survival rates in both univariate and multivariate analysis [14] . However, of the 210 women with reported tumor size at surgery in this current report, we were unable to identify a significant difference in survival in those with tumor size greater or less than 10 cm (5 year-survival of 89% vs. 91%, p = 0.42). Similarly, others have not been able to validate the prognostic significance of tumor size in ovarian SCST [7, 9, 11] .
Since sex cord stromal tumors tend to present at a younger age, fertility-sparing procedures are an important consideration. Some authors have suggested that fertility-sparing procedures may be offered to young patients who strongly desire future fertility. However, such recommendations have mainly been based on expert opinions or limited subset analysis of small studies from single institutions. For example, in a series of 51 women with stage I SCST, 12 women underwent fertilitysparing surgery with three recurrences. Thus, it is difficult to make strong conclusions on the safety of a fertility-sparing approach given the limited size of these studies. While the SEER database does not include information regarding the patient's intent for fertility conservation, we thought it may be reasonable to use younger age as a surrogate marker for patients who might desire fertility. In the 132 patients younger than 50 diagnosed with stage I disease, 61 (46%) underwent standard surgical treatment including a hysterectomy while 71 (54%) had a uterine-sparing procedure. The prognosis for both groups was extremely favorable with equivalent 5-year survivals of 97% and 98% (p = 0.61). These data suggest that uterine-sparing surgery may be a safe alternative approach in the surgical management of these young patients. Experts have claimed that a more conservative approach involving unilateral salpingo-oophorectomy with careful staging may be reasonable in younger women with stage IA SCST who desire to retain fertility [15] . However, it is important to note that although SCST are usually unilateral, 2-8% of the cases are bilateral [2, 3, [8] [9] [10] 12, 16] . Moreover, it is it is prudent to perform an endometrial biopsy to rule out a concurrent uterine cancer. Lastly, it is reasonable to consider a completion total hysterectomy with unilateral salpingo-oophorectomy after childbearing; however, the benefits of this approach remain to be proven. Clearly, these patients need to be counseled regarding the potential risk associated with conservative surgery.
The limitations of our study include the lack of information on surgeon specialty, extent of residual disease, adjuvant chemotherapy, subsequent cytoreductive surgeries, and lack of a central pathology review. Furthermore, even though we showed no survival differences in those who underwent conservative surgery, these findings may be confounded by the selection of potentially healthier patients with less aggressive tumors. Given that SEER does not provide past medical information on prior hysterectomy or subsequent surgeries, the limitations of these data can further confound our results. Despite the lack of evidence showing a survival benefit, postoperative adjuvant therapy is typically advised for patients with stage II-IV SCST given the risk of disease progression and recurrence. In addition, those with stage I disease with large tumor size high mitotic index or tumor rupture are also considered for chemotherapy. Chemotherapy typically involves platinum-based treatments including bleomycin/eptoposide/cisplatin vs. etoposide/cisplatin, and paclitaxel and carboplatin [15] . The role of adjuvant radiation therapy in granulosa cell tumors remains controversial. However, granulosa cell tumors are radiosensitive [17, 18] . Several studies have reported prolonged survival in selected patients treated for recurrent or advanced stage disease [19, 20] .
Although there was no central pathology review on these cases, previous studies have shown that there are no significant discrepancies between registry and referral pathologists. Piver et al. reviewed slides from a large cancer registry and found a 95.3% complete agreement between pathologists on the disease site of origin [21] . In addition, Tyler et al. performed slide reviews on 477 women diagnosed with ovarian, breast, or endometrial cancer and compared the diagnoses of pathologists contributing to tumor registries affiliated with the SEER program to an expert panel of three gynecologic pathologists [22] . They found an overall agreement of 97% for overall cancers, and the agreement for major cellular subtypes of ovarian cancer was 73% for endometrioid and 100% for clear cell carcinomas.
This current study consists of an unselected group of patients spanning across 12 U.S. regions, thus minimizing selection and surveillance biases often associated with clinical trials and studies from single academic institutions. Due to the large numbers of patients, the study cohort could be divided into subgroups, allowing for the analysis of specific subgroups. This current report is the largest series to date on SCST of the ovary showing that younger age and early-stage disease are important predictors for improved disease-specific survival. Furthermore, conservative surgical treatment for early-staged patients wishing to retain fertility appears to be a safe alternative.
